Effectiveness of a Triple Antiarrhythmic Drug Strategy for Arrhythmia Recurrence after Persistent Atrial Fibrillation Ablation.

IF 1.7 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Pace-Pacing and Clinical Electrophysiology Pub Date : 2024-10-09 DOI:10.1111/pace.15083

Shuyu Jin, Haowei Chen, Xianhong Fang, Hongtao Liao, Xianzhang Zhan, Lu Fu, Junrong Jiang, Xingdong Ye, Huiyi Liu, Yanlin Chen, Sijia Pu, Shulin Wu, Hai Deng, Weidong Lin, Yumei Xue

{"title":"Effectiveness of a Triple Antiarrhythmic Drug Strategy for Arrhythmia Recurrence after Persistent Atrial Fibrillation Ablation.","authors":"Shuyu Jin, Haowei Chen, Xianhong Fang, Hongtao Liao, Xianzhang Zhan, Lu Fu, Junrong Jiang, Xingdong Ye, Huiyi Liu, Yanlin Chen, Sijia Pu, Shulin Wu, Hai Deng, Weidong Lin, Yumei Xue","doi":"10.1111/pace.15083","DOIUrl":null,"url":null,"abstract":"Background and objective: Treating recurrent atrial arrhythmias after persistent atrial fibrillation (PeAF) ablation is often challenging. This single-center, prospective study aimed to observe the effectiveness of different combinations of oral antiarrhythmic drugs (AADs) in reverting to sinus rhythm (SR) in patients with recurrent atrial arrhythmias after PeAF ablation.Methods: Forty-five patients who experienced recurrent atrial arrhythmias after PeAF ablation were included. Based on their medication regimens, patients were divided into two groups, with the study group being a triple-drug group (digoxin combined with amiodarone/ propafenone and β-blocker), and the control group being a non-triple-drug group.Results: The rate of reversion to SR was significantly higher in the study group (n = 29) than in the control group (n = 16) at 3 weeks (34.48% vs. 0%, p < 0.01) and 1 month (44.84% vs. 6.25%, p = 0.02) after initiating AADs. No patients with asymptomatic bradycardia were observed in either group.Conclusions: For patients with recurrent atrial arrhythmias after PeAF ablation, a regimen of low-dose digoxin combined with amiodarone/propafenone and β-blocker may effectively improve short-term reversion rates.","PeriodicalId":54653,"journal":{"name":"Pace-Pacing and Clinical Electrophysiology","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pace-Pacing and Clinical Electrophysiology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1111/pace.15083","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Treating recurrent atrial arrhythmias after persistent atrial fibrillation (PeAF) ablation is often challenging. This single-center, prospective study aimed to observe the effectiveness of different combinations of oral antiarrhythmic drugs (AADs) in reverting to sinus rhythm (SR) in patients with recurrent atrial arrhythmias after PeAF ablation.

Methods: Forty-five patients who experienced recurrent atrial arrhythmias after PeAF ablation were included. Based on their medication regimens, patients were divided into two groups, with the study group being a triple-drug group (digoxin combined with amiodarone/ propafenone and β-blocker), and the control group being a non-triple-drug group.

Results: The rate of reversion to SR was significantly higher in the study group (n = 29) than in the control group (n = 16) at 3 weeks (34.48% vs. 0%, p < 0.01) and 1 month (44.84% vs. 6.25%, p = 0.02) after initiating AADs. No patients with asymptomatic bradycardia were observed in either group.

Conclusions: For patients with recurrent atrial arrhythmias after PeAF ablation, a regimen of low-dose digoxin combined with amiodarone/propafenone and β-blocker may effectively improve short-term reversion rates.

查看原文本刊更多论文

三联抗心律失常药物策略对持续性心房颤动消融术后心律失常复发的疗效。

背景和目的：治疗持续性心房颤动（PeAF）消融术后复发的房性心律失常通常具有挑战性。这项单中心前瞻性研究旨在观察不同口服抗心律失常药物（AADs）组合对 PeAF 消融术后复发性房性心律失常患者恢复窦性心律（SR）的有效性：方法：纳入 45 例 PeAF 消融术后复发房性心律失常的患者。研究组为三联药物组（地高辛联合胺碘酮/普罗帕酮和β-受体阻滞剂），对照组为非三联药物组：3周后，研究组（29 人）的 SR 恢复率明显高于对照组（16 人）（34.48% 对 0%，P 结论：研究组的 SR 恢复率明显高于对照组（34.48% 对 0%，P 结论：研究组的 SR 恢复率明显高于对照组（34.48% 对 0%，P 结论）：对于 PeAF 消融术后复发房性心律失常的患者，小剂量地高辛联合胺碘酮/丙帕酮和β-受体阻滞剂可有效提高短期转复率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pace-Pacing and Clinical Electrophysiology 医学-工程：生物医学

CiteScore

2.70

自引率

5.60%

发文量

209

审稿时长

2-4 weeks

期刊介绍： Pacing and Clinical Electrophysiology (PACE) is the foremost peer-reviewed journal in the field of pacing and implantable cardioversion defibrillation, publishing over 50% of all English language articles in its field, featuring original, review, and didactic papers, and case reports related to daily practice. Articles also include editorials, book reviews, Musings on humane topics relevant to medical practice, electrophysiology (EP) rounds, device rounds, and information concerning the quality of devices used in the practice of the specialty.